BostonGene to Present High-Impact AI Models and Biomarker-Driven Frameworks at EHA2026 Congress

Key Takeaways

• Six BostonGene abstracts accepted for EHA 2026, highlighting AI-driven multiomics
• Lymphly classifier identifies BN2 subtype as high‑risk in large B‑cell lymphoma
• Integrated TP53 loss and aneuploidy improves DLBCL risk stratification
• Transcriptomic model separates multiple myeloma patients for aggressive frontline therapies
• Immune profiling shows tazemetostat priming boosts CAR‑T efficacy in B‑cell lymphomas

Pulse Analysis

Artificial intelligence is reshaping hematology by turning massive multi‑omics datasets into clinically actionable insights. At the EHA 2026 Congress, BostonGene will showcase how its platform fuses genomic, transcriptomic, and immune profiling to uncover disease mechanisms that were previously hidden. This convergence aligns with a broader industry shift toward data‑centric drug development, where predictive models inform everything from patient enrollment to endpoint selection, ultimately shortening development timelines and lowering costs.

Among the six abstracts, the Lymphly classifier stands out for isolating the BN2 subtype of large B‑cell lymphoma, a group linked to poorer survival after CAR‑T therapy. By explicitly modeling TP53 loss‑of‑function and aneuploidy, BostonGene provides a nuanced view of tumor biology that helps developers design trials targeting these resistance pathways. A separate transcriptomic risk‑stratification tool segments newly diagnosed multiple myeloma patients, flagging those who could benefit from aggressive bispecific or CAR‑T regimens, thereby improving frontline decision‑making.

For biopharma, these validated AI models translate into tangible competitive advantages. Biomarker‑driven patient selection reduces the risk of late‑stage trial failures, while real‑time immune profiling informs combination strategies, such as tazemetostat priming to enhance CAR‑T durability. As regulators increasingly demand precision evidence, BostonGene’s AI decision layer positions partners to meet those expectations, accelerate approvals, and deliver personalized therapies to patients faster. The company’s collaborations with top academic centers further cement its role as a catalyst for next‑generation hematologic innovation.